This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ALK To Present At Two Upcoming 2013 Investor Conferences

COPENHAGEN, Denmark, Oct. 30, 2013 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Credit Suisse 2013 Healthcare Conference in Scottsdale, Arizona, USA and at the Jefferies 2013 London Healthcare Conference, UK.

Flemming Pedersen, CFO and EVP, will provide an overview of the Company and its key programmes at:

  • Credit Suisse 2013 Healthcare Conference at The Phoenix, Scottsdale, Arizona, USA on Wednesday, 13 November at 3.30 PM Mountain Standard Time

Jens Bager, President and CEO, will provide an overview of the Company and its key programmes at: 

  • Jefferies 2013 London Healthcare Conference at The Waldorf Hilton, London, UK on Wednesday, 20 November at 2.20 PM Greenwich Mean Time

ALK-Abello A/S

Jens Bager President and CEO

For further information please contact:

Investor Relations:

Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609-466-0466

Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy - a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck (MSD outside the USA and Canada) and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs